NCT00799513 - Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2017

Study Completion Date

August 31, 2021

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

Lenalidomide

single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.

Trial Locations (1)

20132

San Raffaele Scientific Institute, Milan